Endovascular treatment of malignant superior vena cava syndrome secondary to lung cancer
Calsina Juscafresa L (1), Gil Bazo I (2), Grochowicz L (1), Páramo Alfaro M (3), López-Picazo González JM (2), Moreno Jiménez M (4), Bilbao Jaureguizar JI (3).
(1a) Vascular Surgery , Clínica Universidad de Navarra , Pamplona , Spain.
(2b) Oncology , Clínica Universidad de Navarra , Pamplona , Spain.
(3c) Interventional Radiology , Clínica Universidad de Navarra , Pamplona , Spain.
(4d) Radiation Oncology , Clínica Universidad de Navarra , Pamplona , Spain.
Superior Vena Cava obstruction results in severe oedema of the upper thorax. Endovascular treatment allows a rapid restoration of the blood flow with a rapid resolution of symptoms. We retrospectively report a single institution's experience in stent placement for malignant Superior Vena Cava Syndrome (SVCS) caused by lung cancer.
Thirty-three consecutive patients (23 men, 10 women; median age, 57.6 years; range 34-71 years) who underwent endovascular SVCS palliative treatment were enrolled between August 2002 and June 2015. All patients presented SVCS secondary to lung cancer. Signs and symptoms of SVCS were scored.
All procedures were successfully completed (100% technical success rate). Twenty-eight patients showed a progressive clinical improvement after endovascular treatment of SVCS (84.8% clinical success rate) within 48 hours, there were five clinical failures which improved progressively with posterior radiotherapy. During follow-up, three patients (9%) suffered intra or post-procedural complications (1 cardiac arrhythmia, 2 stent thrombosis).
Stent placement in malignant SVCS seems to be an effective and rapid treatment for the relief of symptoms and quality of life improvement with a relatively low complications rate with a rapid resolution of symptoms. Therefore, it should be seriously considered as the first option in the SVC obstruction treatment.
CITATION Hosp Pract (1995). 2017 Jun 26:1-6. doi: 10.1080/21548331.2017.1342507